ClinicalTrials.gg

Program

sigvotatug vedotin

Also written as “Sigvotatug Vedotin”.

In Pfizer's pipeline, Integrin beta-6-directed antibody-drug conjugate. Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Pfizer.

Furthest: phase 3, since Aug 21, 20234 company-led studies, 3 open or runningNext primary completion: Jun 16, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer43 open or runningphase 3since Aug 21, 2023May 12, 2020Jun 16, 2027phase 1 · NCT04389632
  • Named in Pfizer’s own pipeline as sigvotatug vedotin PF-08046047, phase 3, as of Nov 3, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 12, 2020First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT04389632 · 1,006 planned · United States, France, South Korea and more
  2. Aug 21, 2023Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06012435 · 762 enrolled · United States, Argentina, Australia and more
  3. Jul 22, 2024Phase 1 study in Carcinoma, Non-Small-Cell LungNCT06549816 · 6 enrolled · China
  4. Dec 26, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06758401 · 714 planned · United States, Argentina, Australia and more

Ahead

  1. Jun 16, 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT04389632
  2. Sep 5, 2028Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT06758401

TargetBeta

“Integrin beta-6-directed antibody-drug conjugate”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against integrin beta-6 (IB6) conjugated, via a protease-cleavable linker, to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic act…”NCIt, read by Claude
“Integrin beta-6 binding agent”ChEMBL 37, by rule

Other programs on ITGB6

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06758401Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3RecruitingSep 5, 2028714
NCT06549816Carcinoma, Non-Small-Cell Lung · China1CompletedNov 18, 20256
NCT06012435Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3Active, not recruitingMay 18, 2026762
NCT04389632Carcinoma, Non-Small-Cell Lung · United States, France, South Korea and more1RecruitingJun 16, 20271,006

How it is read

Names in the registry

  • “sigvotatug vedotin”, 3 entries
  • “Sigvotatug Vedotin”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.